Huang Shu-Hua, Chuang Hui-Ching, Chien Chih-Yen, Chang Yen-Hsiang, Hung Bor-Tau, Fang Fu-Ming, Chang Chiung-Chih
Department of Nuclear Medicine, Kaohsiung Chang Gung Memorial Hospital and Chang Gung University College of Medicine, Kaohsiung, Taiwan.
Kaohsiung Chang Gung Head and Neck Oncology Group, Cancer Center, Kaohsiung Chang Gung Memorial Hospital, Kaohsiung, Taiwan.
Q J Nucl Med Mol Imaging. 2018 Dec;62(4):436-444. doi: 10.23736/S1824-4785.16.02851-X. Epub 2016 Mar 23.
Distinguishing benign complications after concurrent chemoradiotherapy (CCRT) from a local residual tumor in advanced head and neck squamous cell carcinoma (HNSCC) remains a clinical challenge. In this study, we propose criteria when considering physiological uptake patterns on F-18-fluorodeoxyglucose (FDG) PET/CT in patients with advanced HNSCC after CCRT.
We retrospectively reviewed FDG PET/CT images of 62 patients with advanced HNSCC, which were taken within 16 weeks following CCRT. Visual interpretation criteria were rated by three nuclear medicine physicians, independently, according to the uptake patterns of the primary site. The Cohen k coefficient was calculated to assess inter-reader agreement. The histology of the primary site within a 1 month of the PET/CT study was used as the gold standard for sensitivity, specificity, positive predictive value and negative predictive value.
PET/CT was arranged at a median interval of 10.5 weeks (range 4-16 weeks) after CCRT, and the pathologic residual rate was 55.7% at the primary site. The sensitivity, specificity, positive predictive value, negative predictive value, and accuracy of identifying residual disease were 91.1%, 50.0%, 68.9%, 82.3%, and 72.6%, respectively, by the previously established criteria, and 88.2%, 92.9%, 93.8%, 86.7%, and 90.3%, respectively, by our physiology-based criteria. Our visual rating criteria corrected 12 of 14 (84.6%) false-positive results from the established criteria, while two more false-negative cases identified with our criteria were proven to be small residual tumors.
By incorporating physiological changes following CCRT, our visual rating criteria improved the accuracy of the currently used FDG PET/CT visual rating system, especially the number of false-positive cases with advanced HNSCC after CCRT.
在晚期头颈部鳞状细胞癌(HNSCC)中,区分同步放化疗(CCRT)后的良性并发症与局部残留肿瘤仍是一项临床挑战。在本研究中,我们提出了在考虑CCRT后晚期HNSCC患者的F-18氟脱氧葡萄糖(FDG)PET/CT生理性摄取模式时的标准。
我们回顾性分析了62例晚期HNSCC患者的FDG PET/CT图像,这些图像是在CCRT后16周内获取的。由三名核医学医师根据原发部位的摄取模式独立进行视觉解读标准评分。计算Cohen k系数以评估阅片者间的一致性。PET/CT检查后1个月内原发部位的组织学检查结果用作敏感性、特异性、阳性预测值和阴性预测值的金标准。
CCRT后PET/CT的中位安排时间为10.5周(范围4 - 16周),原发部位的病理残留率为55.7%。根据先前确立的标准,识别残留疾病的敏感性、特异性、阳性预测值、阴性预测值和准确性分别为91.1%、50.0%、68.9%、82.3%和72.6%,而根据我们基于生理学的标准分别为88.2%、92.9%、93.8%、86.7%和90.3%。我们的视觉评分标准纠正了既定标准中14例(84.6%)假阳性结果中的12例,而我们的标准识别出的另外两例假阴性病例被证实为小残留肿瘤。
通过纳入CCRT后的生理变化,我们的视觉评分标准提高了当前使用的FDG PET/CT视觉评分系统的准确性,尤其是CCRT后晚期HNSCC假阳性病例的数量。